Activation of the Extracellular Signal-Regulated Kinase 1/2 Pathway by AAV Gene Transfer Protects Retinal Ganglion Cells in Glaucoma
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Glaucoma is the second leading cause of blindness in the world. Loss of vision in glaucomatous optic neuropathy is caused by the selective degeneration of retinal ganglion cells (RGCs). Ocular hypertension is a major risk factor in glaucoma, but visual field defects continue to progress in some patients despite the use of drugs that lower intraocular pressure. At present, there are no effective neuroprotective strategies for the treatment of this disease. The extracellular signal-regulated kinase (Erk) 1/2 pathway is an evolutionarily conserved mechanism used by several peptide factors to promote cell survival. Here we tested if selective activation of Erk1/2 protected RGCs in a rat model of experimental glaucoma. We used recombinant adeno-associated virus to transduce RGCs with genes encoding constitutively active or wild-type MEK1 (approved gene symbol MAP2K1), the upstream activator of Erk1/2. MEK1 gene transfer into RGCs markedly increased neuronal survival: 1366 +/- 70 RGCs/mm(2) (mean +/- SEM) were alive in the dorsal retina at 5 weeks after ocular hypertension surgery, a time when only 680 +/- 86 RGCs/mm(2) of these neurons remained in control eyes. We conclude that the Erk1/2 pathway plays a key role in the protection of RGCs from ocular hypertensive damage. This study identifies a novel gene therapy strategy in which selective activation of the Erk1/2 signaling pathway effectively slows cell death in glaucoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944
Mansour-Robaey, S., Clarke, D. B., Wang, Y. C., Bray, G. M., & Aguayo, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1632 · Cited by 731
Adeno-associated virus general transduction vectors: analysis of proviral structures
McLaughlin, S. K., Collis, P., Hermonat, P. L., & Muzyczka, N. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1963-1973.1988 · Cited by 348
Apoptosis of Retinal Ganglion Cells in Glaucoma
Nickells, R. W. (1999) · Survey of Ophthalmology · doi:10.1016/s0039-6257(99)00029-6 · Cited by 232
Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV
Dudus, L., Anand, V., Acland, G. M., Chen, S.-J., Wilson, J. M., Fisher, K. J., Maguire, A. M., & Bennett, J. (1999) · Vision Research · doi:10.1016/s0042-6989(98)00308-3 · Cited by 160 · cited 2×
“We observed identical expression of AAVmediated MEK proteins at 4 and 10 weeks following administration of viral vectors, consistent with previous observations that AAV vectors mediate long-term transgene expression in the adult retina [18,20,21].”
BackgroundResultGene delivery to the eye using adeno-associated viral vectors
Martin, K. R. G., Klein, R. L., & Quigley, H. A. (2002) · Methods · doi:10.1016/s1046-2023(02)00232-3 · Cited by 149 · cited 1×
“N75% of RGCs can be effectively infected with recombinant AAV [18,23–25].”
BackgroundHarvey, A. R., Kamphuis, W., Eggers, R., Symons, N. A., Blits, B., Niclou, S., Boer, G. J., & Verhaagen, J. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1168 · Cited by 114
Cited by
The molecular basis of retinal ganglion cell death in glaucoma
Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., & Di Polo, A. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.002 · Cited by 971
Self-citationOncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells
Yin, Y., Henzl, M. T., Lorber, B., Nakazawa, T., Thomas, T. T., Jiang, F., Langer, R., & Benowitz, L. I. (2006) · Nature Neuroscience · doi:10.1038/nn1701 · Cited by 515
Cuenca, N., Fernández-Sánchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., & Pinilla, I. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.07.001 · Cited by 401
Leaver, S. G., Cui, Q., Plant, G. W., Arulpragasam, A., Hisheh, S., Verhaagen, J., & Harvey, A. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302791 · Cited by 271
The Role of Inflammation in the Pathogenesis of Glaucoma
Vohra, R., Tsai, J. C., & Kolko, M. (2013) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.08.010 · Cited by 214
Gene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
Krishnan, A., Fei, F., Jones, A., Busto, P., Marshak-Rothstein, A., Ksander, B. R., & Gregory-Ksander, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601488 · Cited by 68
“Over the past decade, gene therapy delivering neurotrophins (58), antiapoptotic genes (57), and transcription factors (75) to the retina has been tested as a treatment in animal models of glaucoma.”
BackgroundDendritic and Synaptic Protection: Is It Enough to Save the Retinal Ganglion Cell Body and Axon?
Morquette, J. B., & Di Polo, A. (2008) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e318177edf0 · Cited by 51
Teo, K. Y. C., Lee, S. Y., Barathi, A. V., Tun, S. B. B., Tan, L., & Constable, I. J. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24333 · Cited by 33
Metadata
- Authors
- Zhou, Y., Pernet, V., Hauswirth, W. W., & Di Polo, A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 12
- Issue
- 3
- Pages
- 402-412
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2004388484
- Cited by
- 103
- References
- 7
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.